Idiopathic Pulmonary Fibrosis News and Research

RSS
Pulmonary fibrosi is a condition in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. The development of the scarred tissue is called fibrosis. As the lung tissue becomes thicker, your lungs lose their ability to move oxygen into your bloodstream. As a result, your brain and other organs don't get the oxygen they need.

In some cases, doctors can find out what's causing the fibrosis. But in most cases, they can't find a cause. They call these cases idiopathic pulmonary fibrosis (IPF). IPF is a serious condition. About 200,000 Americans have it. About 50,000 new cases are diagnosed each year. IPF mostly affects people who are 50 to 75 years of age. IPF varies from person to person. In some people, the lung tissue quickly becomes thick and stiff. In others, the process is much slower. In some people, the condition stays the same for years. IPF has no cure yet. Many people live only about 3 to 5 years after diagnosis. The most common cause of death related to IPF is respiratory failure.
FibroGen, Astellas initiate Phase 2 study of ASP1517/FG-4592 for treatment of anemia linked with CKD

FibroGen, Astellas initiate Phase 2 study of ASP1517/FG-4592 for treatment of anemia linked with CKD

AIFA approves pricing and reimbursement conditions for InterMune's Esbriet

AIFA approves pricing and reimbursement conditions for InterMune's Esbriet

PRISM Pharma announces closing of $15 million Series C financing

PRISM Pharma announces closing of $15 million Series C financing

MUC5B gene variation improves survival in patients with idiopathic pulmonary fibrosis

MUC5B gene variation improves survival in patients with idiopathic pulmonary fibrosis

Boehringer Ingelheim's tiotropium shows promising results in patients with severe persistent asthma

Boehringer Ingelheim's tiotropium shows promising results in patients with severe persistent asthma

Boehringer Ingelheim to highlight respiratory research work at ATS 2013

Boehringer Ingelheim to highlight respiratory research work at ATS 2013

Boehringer Ingelheim updates HCPs, patients on COMBIVENT RESPIMAT Inhalation Spray

Boehringer Ingelheim updates HCPs, patients on COMBIVENT RESPIMAT Inhalation Spray

Study identifies seven new genetic regions associated with pulmonary fibrosis

Study identifies seven new genetic regions associated with pulmonary fibrosis

Study shows TOLLIP gene variant is linked to increased mortality risk in IPF patients

Study shows TOLLIP gene variant is linked to increased mortality risk in IPF patients

Study finds genetic variation is associated with pulmonary fibrosis risk

Study finds genetic variation is associated with pulmonary fibrosis risk

New study examines role of mast cells in development of idiopathic pulmonary fibrosis

New study examines role of mast cells in development of idiopathic pulmonary fibrosis

Scientists identify potential treatment for idiopathic pulmonary fibrosis

Scientists identify potential treatment for idiopathic pulmonary fibrosis

CPF and PFF to partner with ATS to fund pulmonary fibrosis research

CPF and PFF to partner with ATS to fund pulmonary fibrosis research

New data from Boehringer Ingelheim's tiotropium Respimat Phase III UniTinA-asthma programme

New data from Boehringer Ingelheim's tiotropium Respimat Phase III UniTinA-asthma programme

Celtaxsys commences CTX-4430 Phase 1 study to treat pulmonary inflammation

Celtaxsys commences CTX-4430 Phase 1 study to treat pulmonary inflammation

Chinese herbs may show significant benefits for patients with NSCLC, IPF and influenza

Chinese herbs may show significant benefits for patients with NSCLC, IPF and influenza

New nanodevice lays foundations for future development of novel therapies against aging

New nanodevice lays foundations for future development of novel therapies against aging

InterMune receives Health Canada approval for Esbriet to treat idiopathic pulmonary fibrosis

InterMune receives Health Canada approval for Esbriet to treat idiopathic pulmonary fibrosis

Coalition for Pulmonary Fibrosis announces winners of 2012 annual awards for distinguished service

Coalition for Pulmonary Fibrosis announces winners of 2012 annual awards for distinguished service

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.